flâneur

Some questions about biotech that I find interesting | Alex’s blog

atelfo.github.io · 4,097 words · saved by 1 readers

This is a list of biotech-themed questions that I find interesting, inspired by other similar lists. One day, I might turn these into blog posts; if you want to collaborate on a post, chat about anything in this list, or send me relevant readings, please do get it touch! The most commonly used indicator of biopharmaceutical industry R&D efficiency is the number of FDA approved drugs per billion dollars of real R&D spend. On this metric, the trend in industry R&D efficiency looks pretty dismal (see Eroom’s law). While a useful indicator, Eroom’s law is flawed in some important ways. First, it doesn’t capture an important output of research, which are indication expansions of already approved drugs. Many of today’s leading drugs are approved for multiple indications. For instance, Humira, a top-selling autoimmune disease drug, is FDA approved for 9 separate indications. Second, Eroom’s law mixes the effects of fewer successes with rising costs without giving a clear picture of which fac

This is a list of biotech-themed questions that I find interesting, inspired by other similar lists . One day, I might turn these into blog posts; if you want to collaborate on a post, chat about anything in this list, or send me relevant readings, please do get it touch! Table of contents What ‘outcomes’ are we getting per dollar of pharmaceutical industry R&D spend? Why do large pharmaceutical companies tend to settle around $50 billion in annual revenues? Are foundations (or family ownership) the optimal governance structures for large pharmaceutical companies? Was externalization good for

related reading